Oncology
Rheumatology
Neurology
Other Products
Nintedanib
Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, systemic sclerosis associated interstitial lung disease (SSc-ILD).